利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

40 条记录 (耗时 0.031 秒)

    Benzodiazepine antagonistic .beta.-carboline derivatives and compositions thereof
    1.
    发明授权
    Benzodiazepine antagonistic .beta.-carboline derivatives and compositions thereof 失效
    苯并二氮对抗β-咔啉衍生物及其组合物

    公开(公告)号：US4600715A

    公开(公告)日：1986-07-15

    申请号：US623671

    申请日：1984-06-22

    申请人： Andreas Huth ,  Ralph Schmiechen ,  Dieter Seidelmann ,  Dieter Rahtz ,  Mogens Engelstoft ,  Claus T. Braestrup

    发明人： Andreas Huth ,  Ralph Schmiechen ,  Dieter Seidelmann ,  Dieter Rahtz ,  Mogens Engelstoft ,  Claus T. Braestrup

    IPC分类号： C07D471/10 ,  A61K31/435 ,  A61K31/437 ,  A61P25/00 ,  A61P25/18 ,  C07D471/04 ,  A61K31/68 ,  A61K31/535 ,  C07D403/06 ,  C07D471/06

    CPC分类号： C07D471/04

    摘要： .beta.-carboline derivatives of general Formula I ##STR1## wherein R.sup.3 is ##STR2## wherein R.sup.5 is C.sub.1-5 alkyl, R.sup.6 is lower alkyl, aralkyl, or alkoxyalkyl of up to 7 carbon atoms, and R.sup.7 and R.sup.8 are hydrogen C.sub.1-5 alkyl, or, collectively with the amido nitrogen atom, piperidino,R.sup.4 is hydrogen, C.sub.1-3 alkyl, or CH.sub.2 OR.sup.9 wherein R.sup.9 is C.sub.1-3 alkyl, atoms, andR.sup.A is --COOR.sup.10 ##STR3## wherein R.sup.10 is hydrogen, lower alkyl, alkoxyalkyl or alkenyl of up to 5 carbon atoms, or benzyl, or X is oxygen or sulfur, and R.sup.11 and R.sup.12 each are hydrogen, lower alkyl or alkenyl or, collectively with the amido nitrogen atom, represent a hetero ring, are prepared by conventional methods and exhibit, inter alia, an effect on the central nervous system and are suitable for use as psychopharmaceuticals.

    摘要翻译： 通式Ⅰ的咔啉衍生物，其中R 3是R 5是C 1-5烷基，R 6是至多7个碳原子的低级烷基，芳烷基或烷氧基烷基，R 7和R 8是氢 C 1-5烷基，或与酰氨基氮原子一起为哌啶子基，R 4为氢，C 1-3烷基或CH 2 OR 9，其中R 9为C 1-3烷基，原子，RA为-COOR 10，其中R 10为氢， 至多5个碳原子的低级烷基，烷氧基烷基或链烯基，或苄基，或X为氧或硫，R11和R12各自为氢，低级烷基或烯基，或与酰氨基氮原子一起为杂环 通过常规方法制备并显示出对中枢神经系统的影响，并且适合用作心理药物。

    .beta.-carbolines and their use as medicinal agents
    2.
    发明授权
    .beta.-carbolines and their use as medicinal agents 失效
    β-咔啉及其作为药物的用途

    公开(公告)号：US4894377A

    公开(公告)日：1990-01-16

    申请号：US3179

    申请日：1987-01-14

    申请人： Dieter Seidelmann ,  Ralph Schmiechen ,  Andreas Huth ,  Dieter Rahtz ,  Claus T. Braestrup ,  Mogens Engelstoft

    发明人： Dieter Seidelmann ,  Ralph Schmiechen ,  Andreas Huth ,  Dieter Rahtz ,  Claus T. Braestrup ,  Mogens Engelstoft

    IPC分类号： A61K31/404 ,  A61K31/435 ,  A61K31/437 ,  A61P25/00 ,  A61P25/08 ,  A61P25/18 ,  C07D213/40 ,  C07D471/04

    CPC分类号： C07D471/04

    摘要： .beta.-Carbolines of general Formula I ##STR1## wherein R.sup.3 is ##STR2## or --COOR", wherein R' is C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl and R" is C.sub.1-4 alkyl; R.sup.4 is hydrogen, methyl, ethyl or methoxymethyl; and R.sup.A is ##STR3## wherein X is C.sub.1-12 straight-chain, branched-chain, saturated or unsaturated alkyl or a corresponding alkyl group with a CH.sub.2 -group substituted by a carbonyl group and R"" is one or more of fluorine, chlorine, bromine, or iodine, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, C.sub.1-5 acyloxy, phenyl, C.sub.2-5 alkylenedioxy, trifluoromethyl, nitrilo, nitro or --NR.sup.IV R.sup.V wherein R.sup.IV and R.sup.V, which can be the same or different are hydrogen, C.sub.1-3 alkyl, C.sub.1-5 acyl or phenyl, or collectively with the amido nitrogen atom form a 3- to 6-membered hetero ring, which are prepared conventionally by esterifying a corresponding compound wherein R.sup.A is H or R.sup.3 is --COOH, exhibit effects on the central nervous system and can be used as psychorharmaceuticals.

    摘要翻译： 其中R 3是“或”-COOR“，其中R'是C 1-3烷基或C 3-6环烷基，R”是C 1-4烷基的通式I的化合物< R4是氢，甲基，乙基或甲氧基甲基; 并且RA是，其中X是C 1-12直链，支链，饱和或不饱和的烷基或具有被羰基取代的CH 2 - 的相应烷基，并且R“ 氟，氯，溴或碘，C1-3烷基，C1-3烷氧基，C1-5酰氧基，苯基，C2-5亚烷基二氧基，三氟甲基，次氮基，硝基或-NRIVRV，其中RIV和RV可以相同或 不同的是氢，C 1-3烷基，C 1-5酰基或苯基，或与酰氨基氮原子一起形成3至6元杂环，其通常通过酯化相应的化合物，其中RA是H或R3是 -COOH表现出对中枢神经系统的作用，可用作精神药物。

    Pharmacologically active 3-substituted beta-carbolines
    4.
    发明授权
    Pharmacologically active 3-substituted beta-carbolines 失效

    公开(公告)号：US4435403A

    公开(公告)日：1984-03-06

    申请号：US331740

    申请日：1981-12-17

    申请人： Claus T. Braestrup ,  Jogen A. Christensen ,  Mogens Engelstoft ,  Gunter Neef ,  Ulrich Eder ,  Ralph Schmiechen ,  Andreas Huth ,  Dieter Rahtz ,  Dieter Seidelmann ,  Wolfgang Kehr ,  Dieter Palenschat

    发明人： Claus T. Braestrup ,  Jogen A. Christensen ,  Mogens Engelstoft ,  Gunter Neef ,  Ulrich Eder ,  Ralph Schmiechen ,  Andreas Huth ,  Dieter Rahtz ,  Dieter Seidelmann ,  Wolfgang Kehr ,  Dieter Palenschat

    IPC分类号： A61K31/435 ,  A61K31/44 ,  A61K31/445 ,  A61K31/675 ,  A61P25/00 ,  A61P25/20 ,  C07D209/08 ,  C07D209/20 ,  C07D471/04 ,  C07F9/6561 ,  C07D487/14

    CPC分类号： C07D471/04 ,  C07D209/08 ,  C07D209/20 ,  C07F9/6561

    摘要： 3-substituted beta-carbolines of the formula ##STR1## wherein R.sup.C is hydrogen, lower alkyl, alkoxyalkyl of up to 6 C-atoms, cycloalkyl of 3-6 C-atoms, aralkyl of up to 8 C-atoms, or (CH.sub.2).sub.n OR.sup.20wherein R.sup.20 is alkyl of up to 6 C-atoms, cycloalkyl of 3-6 C-atoms or aralkyl of up to 8 C-atoms and n is an integer of 1 to 3;Y is oxygen, two hydrogen atoms or NOR.sup.1,wherein R.sup.1 is hydrogen, lower alkyl, aryl or aralkyl of up to 6 C-atoms, COR.sup.2, wherein R.sup.2 is lower alkyl of up to 6 C-atoms,or Y is CHCOOR.sup.3, wherein R.sup.3 is hydrogen or lower alkylor Y is NNR.sup.4 R.sup.5,wherein R.sup.4 and R.sup.5 can be the same or different and each is hydrogen, lower alkyl, C.sub.6-10 -aryl, C.sub.7-10 -aralkyl or CONR.sup.6 R.sup.7,wherein R.sup.6 and R.sup.7 can be the same or different and each is hydrogen or lower alkyl or R.sup.4 and R.sup.5 together with the connecting N-atom, for a 5- or 6-membered heterocyclic ring which optionally may also contain an O-atom or up to 3 N-atoms and which optionally may be substituted by a lower alkyl group;Z is hydrogen, or alkoxy or aralkoxy each of up to 10 C-atoms and each optionally substituted by hydroxy, or Z is alkyl of up to 6 C-atoms, C.sub.6-10 -aryl or C.sub.7-10 -aralkyl each of which may optionally be substituted by a COOR.sup.8 -- or a CONR.sup.9 R.sup.10 group,wherein R.sup.8 is alkyl of up to 6 C-atoms, and R.sup.9 and R.sup.10 can be the same or different and each is hydrogen or alkyl of up to 6 C-atoms;or Z is NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above;or Z is NR.sup.11 CHR.sup.12 R.sup.13,wherein R.sup.11 and R.sup.12 each is hydrogen or together form a N.dbd.C double bond,wherein R.sup.13 is C.sub.1-10 -alkyl or NR.sup.14 R.sup.15,wherein R.sup.14 and R.sup.15 are the same or different and each is hydrogen, OH or alkyl or alkoxy each of up to 6 C-atoms,or wherein R.sup.12 and R.sup.13 together are oxygen, in which case, R.sup.11 is hydrogen;or Z is COOR.sup.2 wherein R.sup.2 is as defined above;or Y and Z, together with the connecting C-atom, may form a 5- or 6-membered heterocyclic ring which contains an O-atom, adjoining O- and N-atoms or up to 4 N atoms and which optionally may be substituted by a lower alkyl group, hydroxy or oxo have valuable psychotropic properties which make them useful for example as tranquilizers.

    .beta.-carbolin-3-carboxylic acid derivatives useful for treating anxiety and related disorders
    6.
    发明授权
    .beta.-carbolin-3-carboxylic acid derivatives useful for treating anxiety and related disorders 失效
    可用于治疗焦虑和相关疾病的β-咔啉-3-羧酸衍生物

    公开(公告)号：US5010077A

    公开(公告)日：1991-04-23

    申请号：US188145

    申请日：1988-04-25

    申请人： Claus T. Braestrup ,  Mogens C. Nielsen ,  Joergen A. Christensen ,  Mogens Engelstoft ,  Henning Schou ,  Ulrich Eder ,  Gunter Neef ,  Andreas Huth ,  Dieter Rahtz ,  Ralph Schmiechen

    发明人： Claus T. Braestrup ,  Mogens C. Nielsen ,  Joergen A. Christensen ,  Mogens Engelstoft ,  Henning Schou ,  Ulrich Eder ,  Gunter Neef ,  Andreas Huth ,  Dieter Rahtz ,  Ralph Schmiechen

    IPC分类号： C07D471/04 ,  C07H13/10

    CPC分类号： C07D471/04 ,  C07H13/10

    摘要： A .beta.-carbolin-3-carboxylic acid derivative of the formula ##STR1## wherein: X is oxygen, sulphur or NR.sup.10, wherein R.sup.10 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkenyl, C.sub.3-7 -cycloalkyl or C.sub.3-7 -cycloalkenyl;R.sup.3 is (a) C.sub.1-10 -alkoxy, C.sub.1-10 -alkenyloxy, C.sub.6-10 -aryloxy, C.sub.7-11 -aralkoxy or C.sub.8-12 -aralkenyloxy, each optionally substituted with one or more hydroxy groups, halogen atoms, CF.sub.3 groups, C.sub.1-10 -alkoxy groups or C.sub.2-4 -alkenyloxy groups or each optionally substituted with an amino, di-C.sub.1-6 -alkylamino, C.sub.1-10 -alkoxycarbonyl or C.sub.1-10 -alkenyloxycarbonyl group; or (b) NR.sup.11 R.sup.12, wherein R.sup.11 and R.sup.12 are the same or different and each is (i) hydrogen, (ii) hydroxy, (iii) C.sub.1-10 -alkyl, (iv) C.sub.2-10 -alkenyl, (v) C.sub.6-10 -aryl, (vi) C.sub.7-11 -aralkyl, (vii) C.sub.8-12 -aralkenyl, (viii) C.sub.3-7 -cycloalkyl, or (ix) C.sub.3-7 -cycloalkenyl, each of groups (iii)-(ix) optionally substituted with hydroxy, carboxamido, carboxy, C.sub.1-10 -alkoxycarbonyl or C.sub.1-10 -alkenyloxycarbonyl; or (x) amino optionally substituted with C.sub.1-10 -alkyl, C.sub.2-10 -alkenyl, C.sub.6-10 -aryl, C.sub.7-11 -aralkyl, C.sub.8-12 -aralkenyl, C.sub.3-7 -cycloalkyl or C.sub.3-7 -cycloalkenyl; or wherein R.sup.11 and R.sup.12 together with the connecting nitrogen atom form a 5-, 6- or 7-membered heterocyclic ring, which may also contain one additional N or one O atom, and which may be optionally substituted with the same groups of substituents listed for groups (iii)-(ix) above, with the proviso that R.sup.11 and R.sup.12 cannot both be hydroxy; or wherein X and R.sup.3 together represent a single nitrogen atom;R.sup.4 is hydrogen, C.sub.1-10 -alkyl, C.sub.2-10 -alkenyl, C.sub.3-7 -cycloalkyl, C.sub.3-7 -cycloalkenyl, C.sub.7-10 -aralkyl, C.sub.8-10 -aralkenyl, phenyl, C.sub.7-10 -alkoxyphenyl or C.sub.8-10 -alkenyloxyphenyl;R.sup.A is F, Cl, Br, I, NO.sub.2, NR.sup.13 R.sup.14, NHCOR.sup.13, CN, COOR.sup.13, OR.sup.13, SCH.sub.3 or SO.sub.2 NR.sup.11 R.sup.12, wherein R.sup.13 and R.sup.14 each is hydrogen or C.sub.1-6 -alkyl optionally substituted with hydroxy or halogen; and wherein R.sup.11 and R.sup.12 are as defined above, and wherein there may be 1-4 identical or different R.sup.A 's; andR.sup.9 is hydrogen, C.sub.1-8 -alkyl, C.sub.1-8 -alkenyl, C.sub.1-8 -alkoxycarbonyl, C.sub.1-8 -alkenyloxycarbonyl, or C.sub.1-8 -alkenyloxy;with the proviso that R.sup.11 and R.sup.12 are not both hydrogen, when X is oxygen and when R.sup.4, R.sup.A and R.sup.9 each is hydrogen; that one of R.sup.11 and R.sup.12 is not hydrogen when the other is amino and when X is oxygen and R.sup.4, R.sup.A and R.sup.9 each are hydrogen; and that R.sup.4, R.sup.A and R.sup.9 each is not hydrogen when X is oxygen and R.sup.3 is OCH.sub.3.have valuable pharmacological properties.

    Substituted .beta.-carbolines, and use thereof as medicinal agents
    7.
    发明授权
    Substituted .beta.-carbolines, and use thereof as medicinal agents 失效
    取代的β-咔啉，并将其用作药物

    公开(公告)号：US4623649A

    公开(公告)日：1986-11-18

    申请号：US654594

    申请日：1984-09-26

    申请人： Andreas Huth ,  Ralph Schmiechen ,  Dieter Rahtz ,  Dieter Seidelmann ,  Claus T. Braestrup

    发明人： Andreas Huth ,  Ralph Schmiechen ,  Dieter Rahtz ,  Dieter Seidelmann ,  Claus T. Braestrup

    IPC分类号： A61K31/435 ,  A61P25/00 ,  C07D471/04 ,  A61K31/33

    CPC分类号： C07D471/04

    摘要： Novel substituted .beta.-carboline derivatives of Formula I ##STR1## wherein R.sup.3 is an oxadiazolyl residue of the formula ##STR2## wherein R.sup.5 stands for lower alkyl of up to 3 carbon atoms or an ester ##STR3## with R.sup.6 being hydrogen or lower alkyl of up to 3 carbon atoms, R.sup.4 is hydrogen, lower alkyl of up to 3 carbon atoms, or CH.sub.2 OR.sup.9 wherein R.sup.9 is lower alkyl of up to 3 carbon atoms,R.sup.A is phenyl or a hydrocarbon residue containing 2-10 carbon atoms which can be cyclic or acyclic, saturated or unsaturated, branched or unbranched, and which can optionally be substituted by oxo, formyl OH, O-alkyl of up to 3 carbon atoms or phenyl, and wherein, in a cyclic hydrocarbon residue, a CH.sub.2 -group can be replaced by oxygen,exhibit an effect on the central nervous system and thus are suitable as psychopharmaceuticals.

    摘要翻译： 式I的新型取代的β-咔啉衍生物其中R 3是下式的恶二唑基残基，其中R 5表示至多3个碳原子的低级烷基，或者R 6表示氢或 最多3个碳原子的低级烷基，R4是氢，至多3个碳原子的低级烷基或CH2OR9，其中R9是至多3个碳原子的低级烷基，RA是苯基或含2-10个碳原子的烃基， 可以是环状或非环状，饱和或不饱和的，支链或非支链的，并且其可任选被氧代，甲酰基OH，至多3个碳原子的O-烷基或苯基取代，并且其中在环状烃残基中， 组可以被氧代替，对中枢神经系统有影响，因此适合作为心理药物。

    Substituted 5H-pyrimido[5,4-b]indoles
    9.
    发明授权
    Substituted 5H-pyrimido[5,4-b]indoles 失效
    取代的5H-嘧啶并[5,4-b]吲哚

    公开(公告)号：US4564610A

    公开(公告)日：1986-01-14

    申请号：US562248

    申请日：1983-12-16

    申请人： Dieter Rahtz ,  Andreas Huth ,  Ralph Schmiechen ,  Dieter Seidelmann ,  Wolfgang Kehr ,  Herbert H. Schneider ,  Claus T. Braestrup

    发明人： Dieter Rahtz ,  Andreas Huth ,  Ralph Schmiechen ,  Dieter Seidelmann ,  Wolfgang Kehr ,  Herbert H. Schneider ,  Claus T. Braestrup

    IPC分类号： A61K31/505 ,  A61P25/00 ,  C07D209/42 ,  C07D487/04 ,  C07F9/6561

    CPC分类号： C07D487/04 ,  C07D209/42 ,  C07F9/6561

    摘要： Substituted 5H-pyrimido[5,4-b]indoles of Formula I ##STR1## wherein R.sup.2 is halogen; the oxadiazolyl group ##STR2## wherein R" is lower alkyl with up to 3 carbon atoms; C.sub.1-5 -alkyl, cycloalkyl, aralkyl, or aryl; OR.sup.I, SO.sub.n R.sup.I with n being 0, 1, or 2, or ##STR3## wherein R.sup.I is hydrogen, C.sub.1-5 -alkyl, cycloalkyl, aralkyl, or aryl; ##STR4## wherein R.sup.II and R.sup.III are hydrogen, C.sub.1-5 -alkyl, C.sub.3-5 -alkenyl, cycloalkyl, aralkyl, aryl, or, with the connecting N-atom, a 5- or 6-membered heterocyclic ring; andR.sup.A is hydrogen; the oxadiazolyl group ##STR5## wherein R" is lower alkyl with up to 3 carbon atoms; halogen, nitro, OR.sup.I, SO.sub.n R.sup.I with n being 0, 1, or 2, ##STR6## wherein R.sup.I is hydrogen, C.sub.1-5 -alkyl, cycloalkyl, aralkyl, or aryl; ##STR7## wherein R.sup.II and R.sup.III are hydrogen, C.sub.1-5 -alkyl, cycloalkyl, C.sub.3-5 -alkenyl, aralkyl, aryl, or, with the connecting N-atom, a 5- or 6-membered heterocyclic ring; orPO(OR).sub.2 wherein R is C.sub.1-5 -alkyl, exhibit strong affinity for binding to benzodiazepine receptors.The novel compounds are suitable for use in psychopharmaceutical preparations.

    摘要翻译： 取代的式I的5H-嘧啶并[5,4-b]吲哚其中R 2是卤素; 恶二唑基其中R“是具有至多3个碳原子的低级烷基; C 1-5 - 烷基，环烷基，芳烷基或芳基; ORI，nn为0,1或2，或其中R 1为氢，C 1-5 - 烷基，环烷基，芳烷基或芳基的SO nRI; 其中RII和RIII是氢，C1-5-烷基，C3-5-烯基，环烷基，芳烷基，芳基，或具有连接的N-原子的5-或6-元杂环; RA为氢; 恶二唑基其中R“是具有至多3个碳原子的低级烷基; 卤素，硝基，ORI，nn为0,1或2的SO nRI，其中R 1为氢，C 1-5 - 烷基，环烷基，芳烷基或芳基; 其中RII和RIII是氢，C1-5烷基，环烷基，C3-5-烯基，芳烷基，芳基，或具有连接的N-原子的5或6元杂环; 或其中R为C 1-5 - 烷基的PO（OR）2表现出对苯并二氮杂受体结合的强亲合力。 新型化合物适用于精神药物制剂。